Orkla ASA (ORK) Earnings Call Transcript & Summary
February 13, 2025
Earnings Call Speaker Segments
Annie Bersagel
executiveGood morning, everyone, and welcome to Orkla's presentation of the fourth quarter results. I'm Annie Bersagel, the new Head of Investor Relations and Communication. Nils Selte, our President and CEO, will start things off with a summary of the quarter. Following that, Arve Regland, our CFO, will go through more details on the financials. Before we get to Q&A, Nils will recap the main messages from the quarter. So once the presentation is done, we'll hold a video Q&A with our analyst community, and after that we'll move on to questions from the web. During the presentation, you're welcome to submit questions — this is open to everyone — and we'll take those after the video Q&A with the analysts. Just a quick note to clear up any confusion about some name changes: in our financial statements for the quarter, you may notice that we refer to Orkla ASA as in the consolidated portfolio companies including Orkla ASA. That's the same concept as Orkla headquarters — only the name has changed. Second, two of the portfolio companies have simplified their names since last quarter, so Orkla Foods Europe is now simply Orkla Foods, and Orkla Confectionery & Snacks is now Orkla Snacks.
Annie Bersagel
executiveI'd like to emphasize that the strategy itself hasn't changed at all — we're only simplifying the name. With that, I'll hand things over to you now, Nils.
Nils Selte
executiveThanks, Annie, and good morning, everyone — appreciate you joining the presentation. 2024 marks the first complete year since our transformation into an industrial investment company, and also the first complete year of our 2024 to 2026 strategy period. I'm really happy with the value creation and the strong financial performance across our portfolio companies, so let me walk through a few highlights from 2024. First, profitability in our portfolio companies has improved substantially, with 17% underlying EBIT growth. At the same time, we put significantly more into A&P, which is consistent with our strategy. Cash flow from operation in the consolidated portfolio companies, Orkla ASA included, improved by NOK 1.9 billion versus 2023, lifted by EBIT-adjusted growth and stronger capital discipline. As I mentioned at the Captain Markets Day, driving organic value in our existing portfolio is my number one priority. We keep simplifying the portfolio — we sold Lilleborg to Solenis in June 2024, and in April we also closed the transaction with Rhône for a minority stake in Orkla Food Ingredients. We're still seeing the benefit from that partnership. On the basis of the 2024 results, the Board of Directors plans to propose raising the ordinary dividend for the financial year 2024 to NOK 4.00 per share.
Nils Selte
executiveThe Board is also proposing an extra dividend of NOK 6.00 per share, reflecting solid underlying performance, higher cash conversion, and the divestment of our Hydro Power assets. I've noticed media speculation that our strategy involves breaking up Orkla. Let me be clear: that is not the case. We are pursuing the steps we laid out at the Captain Markets Day. We're driving organic value within the existing portfolio, we're cutting complexity, and we're starting to evaluate opportunities to invest in Orkla's future growth, both organically and via M&A. Our aim is to secure sustainable growth across our portfolio companies while keeping the ordinary dividend stable. We're positioned to seize value accretive opportunities as they come up, yet we're equally committed to walking away from any deal that doesn't serve Orkla's shareholders' best interests. On outlook, as we noted in Q3, raw material price development is still polarized, but we keep expecting prices in some areas to stabilize, cocoa excluded. Moving to the Hydro Power transaction and today's announced sale of Pierre Robert Group. On January 24, we announced the sale of Orkla's full Hydro Power portfolio for NOK 6.1 billion.
Nils Selte
executiveThis has taken quite a while, yet in my view the result is a good one. Although the relevant authorities must still approve the transactions, we anticipate that both will be completed no later than the close of Q3 this year. We also announced today the sale of Pierre Robert Group, which we expect to close by the end of Q1. That company has delivered weak results for several years and is presently carrying out a strategic repositioning. Jotunfjell Partners is better placed than continued ownership by Orkla to support the company's progress at this stage. Selling these two assets allows us to reduce complexity. We further confirm our strategy of establishing Orkla as a leading industrial investment company with a brand and consumer-oriented scope. Turning to the Q4 results. During Q4, we kept enhancing profitability and cash flow, delivering on the financial targets we announced at the Capital Markets Day in November 2023. Orkla's organic growth stood at 3.3% in Q4. Both volume/mix growth and price increases drove this. The consolidated portfolio companies posted underlying EBIT adjusted growth of 13.4%. Keep in mind that apartment deliveries in Orkla Real Estate also made a positive contribution to Group EBIT adjust. Adjusted earnings per share rose 16% versus the same quarter last year.
Nils Selte
executiveDuring Q4, as I mentioned, adjusted underlying EBIT came in at 13.4% across the consolidated portfolio companies, Orkla ASA included. Moving on to a handful of the biggest portfolio companies: Jotun kept posting strong results, among them an impressive 34% return on capital employed measured on a rolling 12-month basis. At Orkla Food, volume growth was once again marginally positive during Q4. The operating margin kept climbing even with higher advertising spend, which is consistent with strategy. Orkla Snacks saw the biscuit factory carry on its recovery, matching what we told you previously. Overall market shares held steady, and volume pressure persisted within the chocolate category. Cocoa market prices climbed sharply over the quarter, and Arve will come back to that point later. In October 2024, the CEO of Orkla Health chose to step down from her role because of a misalignment regarding key priorities. The search to fill her position is moving forward well. Strategy stays unchanged, centered on revitalizing Orkla Health's robust standing in its home markets, creating a sustainable omnichannel platform, and selectively growing international brands. We have 3 consolidated targets from the Capital Markets Day. Together these reflect the combined impact of the portfolio companies as they hit their targets through 2026. With year one of the three-year strategy period now behind us, I'm glad to report substantial growth in underlying EBIT and EBIT margins, even as we raised investments behind our brands.
Nils Selte
executiveOn top of that, the capital we've put to work in these businesses is producing a bigger return. At this point, I'll pass things to Arve, who can walk you through the financials in more detail.
Arve Regland
executiveGood morning, everyone. I'll walk you through the key points from the fourth-quarter financials, beginning with the top line: operating revenues rose 6% to NOK 18.8 billion for the quarter. EBIT adjust for the consolidated portfolio companies was up 8%, lifted by solid underlying growth and better margins. This quarter we saw an EBIT contribution of NOK 143 million from Orkla Real Estate, tied to the handover of 53 apartments in the final phase of the Oslo development project. Hydro Power posted an EBIT of NOK 252 million, a gain of 38% on the back of higher production volume. Please note that as of the first quarter of 2025, Hydro Power will be reported as discontinued operations in the financial statements. At the group level, EBIT rose 25% to NOK 2 billion. Other income and expenses came in at minus NOK 197 million for the quarter, largely reflecting write-downs of intangible assets of NOK 121 million in Pierre Robert and NOK 30 million tied to ongoing restructuring projects in Orkla Foods and Orkla Snacks. Profit from Jotun and other associates was NOK 371 million, in line with the same quarter last year. Jotun delivered 17% EBITDA growth in the quarter, but profit after tax was offset by higher financial costs, including negative currency effects, as well as higher tax costs than in the same quarter last year.
Arve Regland
executiveFor the consolidated portfolio companies, the rolling 12-month adjusted EBIT margin stood at 10.1% in Q4 — that's up 1.1 percentage points versus the prior 12 months. Turning to organic growth, it rose 3.3% during the quarter, with volume/mix adding 1.5%. Taken as a whole, volume/mix growth was positive in each of the four quarters of 2024, with contributions coming broadly from across the portfolio companies. And 2024 reflects a more normalized environment, for both price and volume development. Cash flow from operations totaled NOK 7.9 billion for the full year, which is NOK 1.9 billion higher than last year. That gain came primarily from EBIT growth and reduced net replacement investments, along with our ongoing emphasis on cutting working capital. When you include the cash flow effects from financial investments, taxes, the dividend received from Jotun, and financial expenses, cash flow before capital allocation came to NOK 7.5 billion — NOK 3.1 billion above the prior year. We're also glad to see cash conversion improving across the portfolio companies, hitting 114% at an aggregated level in 2024. The robust cash flow we covered on the previous slide further reinforced the balance sheet in 2024, and at year end, net interest bearing debt was NOK 16 billion, or 1.5 times EBITDA.
Arve Regland
executiveOrkla has a lengthy track record of delivering a steady, rising ordinary dividend to shareholders. As Nils said, the Board plans to put forward a raise in the ordinary dividend to NOK 4.00 per share, along with an extra dividend of NOK 6.00 per share. Assuming the Board formally proposes it and the Annual General Meeting in April gives approval, shareholders will receive the total dividend of NOK 10 per share in early May. Let's now turn to a few more specifics on the portfolio companies, beginning with Jotun, which turned in another strong quarter, with operating revenues up 15%; after adjusting for favorable currency translation effects, operating revenue growth came to 12%. Every segment posted double digit growth, mainly on volume and helped by favorable mix effects. Sales grew in all regions, with Southeast Asia and Pacific seeing an uptick in Q4. Decorative in Scandinavia stayed weak, and the Marine segment took a hit from postponed dry dockings. EBITDA rose by 17%, on the back of higher sales and a better gross margin, helped by raw material prices that were fairly stable. That was more than enough to offset higher operating costs and heavy inflationary pressure in certain markets.
Arve Regland
executiveAs mentioned earlier, higher financial expenses and tax costs weighed on profit after tax. All in all, 2024 proved a very solid year for Jotun, and as we head into 2025, Jotun anticipates continued sales growth above the level of projected market growth. Conversely, operating margins are expected to fall relative to the historically high levels of the last two years. Taking everything together, we expect Jotun to post ’25 results on par with 2024. Orkla Foods saw modest organic growth of 1.1% in the quarter, driven mainly by price. Even so, we are glad to report yet another quarter of positive volume/mix growth across several key markets, particularly Norway and the Czech Republic, whereas other markets experienced softer volume development owing to continued weak purchasing power, campaign phasing, and customer logistics issues. Growth was driven by the grocery trade, while out-of-home channels developed somewhat weakly this quarter. EBITDA came in at just NOK 681 million, which represents reported growth of 7% and underlying growth of 10%. Rolling 12-month EBIT adjust margins now stand at 12.3%, versus 11.1% last year. Stronger cash generation resulted from improved working capital efficiency, particularly inventory reductions.
Arve Regland
executiveOrganic growth at Orkla Snacks came in at 6.2%, mainly driven by price increases in confectionery. Softening chocolate demand following high cocoa prices held volumes back. Cocoa's market price climbed sharply during the quarter, and that will weigh on the next quarter negatively, partly because there is limited short-term ability in the markets to pass on increases in input costs. How the rise in cocoa prices affects consumer chocolate prices and demand across the coming quarters remains uncertain. Mitigating actions are underway and span the whole value chain via portfolio optimization, additional price adjustments, and a full review of the cost base. Our expectation is that cocoa prices will stay higher and be more volatile than previously, though we also expect them to fall to a more sustainable level over time as supply and demand balance out. We saw continued strong volume growth in the quarter for Bubs, thanks to increased production capacity, and for biscuits. EBIT adjust was NOK 424 million, an underlying growth of 21%. Roughly half of the EBIT improvement stems from recovery at the biscuit factory. So, in line with our guidance, a significant portion of the NOK 150 million loss we had in 2023 was recovered.
Arve Regland
executiveFor the quarter, Orkla Food Ingredients posted organic growth of 4%, with volume/mix gains driving that across every cluster. In Bakery, volume increased in most markets—Eastern Europe especially—and Bakery's performance held up well through 2024, growing faster than the market as a whole. Sweet saw growth in all business units, particularly confectionery ingredients and decorations. Plant-based growth came mainly from industrial margarine and non-dairy products. Underlying EBITDA adjust rose 18%, with that increase coming from volume/mix growth across all clusters, most notably Bakery. EBIT adjust for plant-based fell, and as we noted in our Q3 presentation, we were up against strong comparables in the margarine segment in Q4 2023. The cost program in the Sweet cluster, launched in Q3, is on track per plan. We anticipate gradual benefits in 2025, totaling a high double-digit million cost reduction. Orkla Health delivered organic growth of 6.2% for the quarter, stemming from both price and volume/mix across markets. The 2.5% volume/mix growth was fueled by a continued positive trend in the D2C portfolio, along with a strong quarter in Norway, Finland, and Wound Care. Möller's and Jordan kept performing well across markets.
Arve Regland
executiveMargins in food supplements took a hit from higher raw material costs, cod liver oil in particular. EBITDA came in at only NOK 85 million, and versus last year the drop breaks down into two main pieces. First, as our strategy calls for, we're putting money into the organization across both home and international markets to back future growth. Second, roughly NOK 30 million in non-recurring costs relates to organizational changes and cleaning up inventory. Organic growth at Orkla India was minus 3.6%, affected by the timing of financial incentives from the government of India, with NOK 24 million booked in the fourth quarter last year. Those incentives arrived in this year's second and third quarters. Strip out these effects and organic growth was 0.6%, with volume/mix growth of 4%, mainly tied to international sales, while the negative price effect stemmed from passing input cost reductions along to customers. Even with weak sentiment in the domestic market, underlying EBIT adjust growth reached 7%, and 42% when adjusting for the financial incentives. Falling raw material prices and lower fixed costs gave the growth a positive push. Organic growth was flat at the European Pizza Company this quarter. Da Grasso in Poland kept up positive momentum, while consumer sales in Finland and the Netherlands stayed under pressure from weak consumer sentiment.
Arve Regland
executiveAdjusted EBIT landed at NOK 70 million. Versus the same quarter a year earlier, the decline stems from a NOK 7 million write-down of receivables tied to a limited set of franchise businesses. Orkla Home & Personal Care posted 10% organic growth, fuelled by higher volumes in contract manufacturing and helped along by favourable market growth. Growth in underlying adjusted EBIT of 86% came from revenue management, beneficial mix effects and improvements in input costs. Turning to the remaining companies in the transform or exit category — and as Nils noted — we have signed an agreement covering the sale of 100% of the shares in Pierre Robert. The accounting loss we estimate on closing this transaction comes to roughly NOK 40 million, and closing is expected at the end of the first quarter of this year. With that, I'll hand the floor back to you, Nils.
Nils Selte
executiveThanks, Arve. I feel good about what we achieved during 2024. We produced strong gains in profit along with organic growth, and volume/mix was positive. Our Capital Markets Day targets are being met — that includes cutting complexity across our portfolio. In the core, we are showing that value is being created, and we are stepping up how we assess opportunities for growth going forward. I want to use this moment to thank each person across our organization for their commitment and hard work in delivering these good results, and I'm eager to keep moving forward on this journey with all of you in 2025. Before Q&A, I'd like to extend an invitation to our Capital Markets Update on May 28th this year. When May ends, we will be at the midpoint of the strategic period. At the Capital Markets Update, our plan is to provide a fuller picture of how Orkla is advancing toward the targets we set. A great deal of the last two years has gone into talking about Orkla's shift into an industrial investment company, and we now feel real enthusiasm surrounding that. I'm eager for the chance to devote more time to demonstrating the ways we generate value within the underlying portfolio companies. So joining Arve and me on stage will be three CEOs from those portfolio companies: Aku Vikström at Orkla Foods, Ingvill Berg at Orkla Snack, and Johan Clarin at Orkla Food Ingredients.
Nils Selte
executiveOur plan is to provide a progress report and to open things up so you can see the way we generate value at three of the biggest companies in our portfolio. That said, we'll turn it over to Q&A.
Annie Bersagel
executiveThanks. We're moving into the Q&A now, so if you'd like to ask something, please raise your hand. I'll introduce you. Our first question comes from Eirik Rafdal at Carnegie.
Eirik Rafdal
analystYes. Hi, team, thanks for taking my questions. I've got three. If we could start with India, actually, no kind of firm update there. A couple of rumors overnight that you're looking at an outright sale. I sense previously with Orkla that you don't want to fully exit India. Has your thinking changed there? And if so, why? That would be my first question.
Nils Selte
executiveTo start with, we won’t comment on rumors or speculation in the market or media that have no basis. That’s the first point. As we’ve said before, we’ve begun a project to look into the opportunity to access the Indian capital market. That remains the situation.
Eirik Rafdal
analystYeah, that's very clear, Nils — thanks. And sticking with the structural measures, could you update us a little on the transform or exit assets that are still left? What are your plans for those, and how should we be thinking about them? You've been moving pretty fast on structural measures over the last couple of months.
Nils Selte
executiveLike I mentioned earlier, we don’t discuss M&A processes or possible structural deals before we’ve done them, so I can’t offer any guidance there. Right now I’m pleased with how most of the companies are performing, and we’ll come back to you once we have something to share.
Eirik Rafdal
analystThat's reasonable, thanks. Let me try one last question. With the CMD being announced in late May, would it be fair to assume a margin upgrade is on the table, given where you already stand and the divestment over the last year of some of the assets that dilute margin more? How should we think about that?
Nils Selte
executiveThe key aim of that capital markets update isn't really a Capital Markets Day—it's a progress report at the midpoint of our strategy period. As I mentioned, we'll be letting you look under the hood at three of our biggest portfolio companies. That's the core objective: making sure you and our investors genuinely see how value is being created through the new approach to running Orkla and our portfolio companies. That's what that Capital Markets Update is mainly about.
Eirik Rafdal
analystExcellent. I appreciate you fielding my questions.
Annie Bersagel
executivePetter Nystrom from ABG Sundal Collier has the next question.
Petter Nyström
analystYes, appreciate you taking my question. That one concerns Health. Arve, you said you're putting money into future growth here. What should we anticipate for cost development in the Health segment as we go into 2025? Thank you.
Arve Regland
executiveRight, I don’t really expect that to be the case — it was a unique quarter, the fourth quarter, and as I said, a big chunk of the higher cost was truly tied to one-off items. We are still investing to some degree in the organization, though I wouldn’t offer a clear guidance. Still, I’d view the fourth quarter as somewhat unusual on the cost side, and you should expect more normalized levels ahead.
Petter Nyström
analystI appreciate that.
Annie Bersagel
executiveLooks like that was the final one from Teams. So we'll move on to web questions now. Our first comes from Rishabh Jain. There's been some recent talk about a majority stake in MTR being sold — that's the business Orkla India handles — to ITC Limited. Do you have any thoughts on when that deal might close, and what timelines are we looking at? I believe we've already addressed that.
Nils Selte
executiveI believe we’ve already addressed that. We don’t comment on unfounded speculation or rumors, and that’s all.
Annie Bersagel
executiveWe've got another question from Ole Martin Westgaard at DNB Markets. Actually, he has two questions. The first one is about market shares. How do you view your market share development in Q4 and 2024 versus private label? And then there's a second question about cocoa, but maybe we'll take the market share development first.
Nils Selte
executiveTo start with, across the companies in our portfolio we're seeing market share move either positively or sideways, and that's something we're glad about. Looking at private label within the markets where we do business, what we're observing is that it's leveling off. The gains we witnessed during the inflation period are now flattening or holding steadier.
Annie Bersagel
executiveThen the second thing I'd ask is this: for 2025, what share of your cocoa exposure is already hedged?
Arve Regland
executiveWell, we aren't providing explicit guidance on the hedging policy. What we've stated is that volumes are secured for the first quarter, and we'll come back with a fuller update during the first quarter on how we view cocoa price developments and how that impacts our margins and input costs at that point. So as of now, there's no additional guidance on how much we are hedged throughout the year.
Annie Bersagel
executiveThat seems to be the last question we got from the web. So, before we wrap up, I'd like to remind everyone that our first quarter results will be reported on May 9th. Beyond that, thank you for being with us, and please enjoy your day.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Orkla ASA transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Orkla ASA earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Orkla ASA or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.